ᐈ Carthera Raises €42m to Launch Clinical Trials

📢 Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials. The funds will be used to launch a registrational trial of its ultrasound-based medical device SonoCloud to treat recurrent glioblastoma. Carthera also plans to expand its pipeline in the field of neurodegenerative diseases.

📢 Cathera SA closes Series B round at €42m

Introduction:

Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials. Carthera plans to use the funding to launch an open-label registrational trial of its ultrasound-based medical device SonoCloud® to treat recurrent glioblastoma (rGBM) and expand its pipeline in the field of neurodegenerative diseases.

Main points:

The Series B financing round was led by Unorthodox Ventures and also included participation from existing shareholders Supernova Invest, Saint-Genys, and Bouscas Med.
Carthera will use the funding to conduct an open-label registrational trial of its SonoCloud® device to treat recurrent glioblastoma. The trial will evaluate the overall survival of patients undergoing carboplatin chemotherapy and treated with the SonoCloud-9® system to open the Blood Brain Barrier (BBB), comparing it to the standard of care.
The funds will also be used to develop Carthera’s clinical and preclinical pipeline in the field of neurodegenerative diseases. The company is seeking collaborations with pharmaceutical and biotech partners to further utilize its SonoCloud technology in delivering therapies to the brain.
SonoCloud is an ultrasound-based medical device developed by Carthera that temporarily increases the permeability of blood vessels in the brain to improve the delivery of therapeutic molecules. The device offers potential treatment options for brain tumors and Alzheimer’s disease, but it has not yet received approval from EMA or FDA.

Conclusion:

Carthera’s successful Series B financing round will enable the company to launch clinical trials for its SonoCloud device and expand its pipeline in the field of neurodegenerative diseases. The company is actively seeking collaborations to further develop and utilize its innovative ultrasound-based technology in delivering therapies to the brain. If successful, SonoCloud has the potential to provide new treatment options for patients with recurrent glioblastoma and other neurodegenerative diseases.